Endoscopic Solutions News Today

The CEO of Olympus anticipates some negative revenue impact on fiscal 2024 results and as yet uncalculated impact on fiscal 2025.

Other than a modest increase in revenue, all the profitability indicators declined when compared to the same period in fiscal 2023.

Specimen Retrieval Market Projected To Garner Significant Revenues By 2031

Stefan Kaufmann tentatively appointed new Director, Representative Executive Officer, President and CEO as the global medtech leader prepares for the company's next stage of growthTOKYO, Oct 21, 2022 -

Olympus Corporation (Olympus), a global medtech company committed to making people's lives healthier, safer and more fulfilling, today announced the launch of ...

~ To Support More Accurate Diagnosis and Treatment of Pancreaticobiliary and Lung Diseases ~TOKYO & HAMBURG, Oct 7, 2022 - (JCN Newswire) - Olympus Corporation (Olympus), a global medtech company committed

Olympus Corporation and EVIDENT Co., Ltd., a wholly-owned subsidiary of Olympus announced that Olympus concluded a definitive agreement with Bain Capital Private Equity, LP, regarding the transfer ...

Olympus Corporation (“Olympus”) and EVIDENT Co., Ltd. ("Evident"), a wholly-owned subsidiary of Olympus announced today that Olympus concluded a definitive agreement with Bain Capital Private Equity, LP (“Bain Capital”), regarding the transfer of Evident.

Olympus is selling its wholly owned subsidiary EVIDENT Co. Ltd. to Bain Capital. The divestment, which is reportedly worth over $3 billion, will see a

Press release content from PR Newswire. The AP news staff was not involved in its creation.